Royalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020. Repurchased GSK’s full 32% equity stake in Innoviva for $392 million purchase price. Strategically invested an additional $20 million into Entasis Therapeutics Holdings Inc.

Innoviva to repurchase GSK’s current 32% stake in the company for $392 million BURLINGAME, Calif. --(BUSINESS WIRE)--May 20, 2021-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK’s equity stake in Innoviva ,

WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5

Royalties increased by 8% to $89.0 million in the first quarter of 2021, compared to the same quarter in 2020. Invested an additional $20.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP), an anti-infectives leader, in the first quarter of 2021. Deborah L.

MARINA DEL REY, Calif. , March 17, 2021 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today

Royalties increased by 18% to $93.9 million in the fourth quarter of 2020, compared to the same quarter in 2019. Invested $300 million into a fund advised by Sarissa Capital Management LP as a part of a strategic partnership designed to enhance returns on our capital and accelerate execution of our

MARINA DEL REY, Calif. , Jan. 27, 2021 /PRNewswire/ --  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today

Royalties increased by 33% to $92.2 million in the third quarter of 2020, compared to the same quarter in 2019. Invested an additional $12.5 million into the common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives development. BURLINGAME, Calif.

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm LONDON & BURLINGAME, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration

Royalties increased by 7% to $72.4 million in the second quarter of 2020, compared to the same quarter in 2019. Pavel Raifeld named as Chief Executive Officer. Invested $35 million into common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives